rs1800544 — ADRA2A ADRA2A Promoter -1291C>G

Promoter variant that alters alpha-2A adrenergic receptor expression, affecting adrenergic suppression of insulin secretion and lipolysis; C allele carriers show greater susceptibility to antipsychotic- and antidepressant-induced weight gain

See your personal result for ADRA2A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Adrenergic Brake on Fat Storage and Insulin Release

Your nervous system uses adrenaline as a metabolic switch — flooding tissues with it during stress to mobilize energy. In two critical tissues, this signal travels through the alpha-2A adrenergic receptor11 alpha-2A adrenergic receptor
A G-protein-coupled receptor that mediates inhibitory responses to adrenaline and noradrenaline: pancreatic beta cells, where it suppresses insulin secretion, and fat cells, where it applies the brakes on lipolysis (fat breakdown). A variant 1,291 base pairs upstream of the ADRA2A gene (-1291C>G) alters how much of this receptor protein a cell makes — and that difference has measurable consequences for how your body handles metabolic stress and responds to certain medications.

The Mechanism

The ADRA2A gene encodes the alpha-2A adrenergic receptor, which is expressed at high levels in pancreatic beta cells and adipocytes. When adrenaline activates this receptor, it inhibits cAMP production, suppressing both glucose-stimulated insulin secretion and incretin-amplified insulin release via the cAMP/TRPM2 signalling axis22 cAMP/TRPM2 signalling axis
Transient receptor potential melastatin 2 channels couple alpha-2A receptor activation to reduced membrane excitability in beta cells. In adipose tissue, the same inhibitory signal reduces lipolytic flux, favouring fat retention.

The -1291 position lies in the promoter region — the DNA segment that governs how much RNA (and ultimately protein) the gene produces. Small et al. 200633 Small et al. 2006
Small KM et al. Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression. PNAS, 2006 demonstrated that noncoding haplotypes across the ADRA2A gene produce up to 5-fold differences in receptor transcript and surface protein levels across cell lines. Higher receptor density means a stronger adrenergic brake on insulin secretion and a tighter hold on stored fat.

The Evidence

The clearest clinical signal for rs1800544 comes from drug-induced weight gain. Sickert et al. 200944 Sickert et al. 2009
Sickert L et al. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics, 2009 tracked 60 European-Americans on clozapine or olanzapine for 6–14 weeks. C allele carriers (CC + CG) gained 3.73 ± 4.13 kg, compared with just 0.23 ± 2.92 kg for GG homozygotes (p=0.013). The same directionality appeared with the antidepressant mirtazapine: Lee et al. 200955 Lee et al. 2009
Lee HY et al. Association of the adrenergic alpha 2a receptor -1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Brain Research, 2009 found the CC genotype gained more weight after 8 weeks of mirtazapine treatment in 314 MDD patients (p=0.052).

Conversely, when patients were switched from weight-inducing antipsychotics to metabolically neutral alternatives, the GG genotype showed the greatest benefit: Roffeei et al. 201466 Roffeei et al. 2014
Roffeei SN et al. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. Human Psychopharmacology, 2014 found GG carriers lost 1.04 ± 1.63 kg/m² BMI vs only 0.32 ± 1.41 kg/m² for C allele carriers when switching to aripiprazole or ziprasidone (p=0.013).

On metabolic physiology, Rosmond et al. 200277 Rosmond et al. 2002
Rosmond R et al. A C-1291G polymorphism in the alpha2A-adrenergic receptor gene promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. Journal of Internal Medicine, 2002 studied 284 Swedish men and found that heterozygous C/G carriers had impaired dexamethasone suppression (higher post-dex cortisol, p=0.009) and elevated fasting glucose compared with GG homozygotes (p=0.017). The mechanism proposed: altered receptor density destabilises sympathetic–hypothalamic–pituitary–adrenal axis tone, raising ambient cortisol and blunting insulin sensitivity. Separately, Kochetova et al. 201588 Kochetova et al. 2015
Kochetova OV et al. Genetic association of ADRA2A and ADRB3 genes with metabolic syndrome among the Tatars. Genetika, 2015 found GG and GC genotypes were associated with higher fasting insulin and elevated HOMA-IR in Tatar women with metabolic syndrome — a finding that conflicts somewhat with the antipsychotic weight-gain literature and illustrates that the direction of effect likely depends on the specific metabolic context and concomitant treatments.

Practical Actions

The most actionable signal from rs1800544 relates to medications that engage the adrenergic system or carry known weight-gain liabilities. C allele carriers starting clozapine, olanzapine, or mirtazapine face substantially elevated risk of rapid weight accumulation. Pre-emptive monitoring of weight and waist circumference, and selecting metabolically neutral alternatives where clinically appropriate, represents the most evidence-grounded response.

Separately, the G allele is associated with better methylphenidate response in ADHD (Hain et al. 202299 Hain et al. 2022
Hain DT et al. Review and Meta-analysis on the Impact of the ADRA2A Variant rs1800544 on Methylphenidate Outcomes in ADHD. Biological Psychiatry Global Open Science, 2022; OR 3.08, 95% CI 1.71–5.56, p=0.0002 across 9 studies). This is a pharmacogenomic signal with potential utility in paediatric ADHD prescribing decisions.

Interactions

The ADRA2A rs553668 and rs521674 promoter variants tag partially overlapping haplotypes within the same regulatory region, and their combined effects on receptor expression may be additive. The 5-fold expression range reported by Small et al. encompasses multi-SNP haplotypes, not single variants in isolation; users carrying multiple ADRA2A promoter variants may have amplified effects on adrenergic tone.

In the context of obesity genetics, ADRA2A interacts functionally with the beta-3 adrenergic receptor (ADRB3, rs4994) — both regulate sympathetic control of adipose tissue lipolysis from opposing directions. Combined carriership of ADRA2A and ADRB3 risk variants has been explored in metabolic syndrome cohorts.

Drug Interactions

clozapine increased_toxicity literature
olanzapine increased_toxicity literature
mirtazapine increased_toxicity literature
methylphenidate reduced_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard Adrenergic Tone Normal

Typical adrenergic receptor expression; lower susceptibility to drug-induced weight gain

You carry two copies of the G allele at the ADRA2A promoter, the GRCh38 reference genotype at this position. The G allele is the minority allele globally (about 33% of people worldwide, 25% of Europeans), so this is a less common genotype. Studies of antipsychotic and antidepressant-induced weight gain consistently show that GG individuals gain substantially less weight on agents like clozapine, olanzapine, and mirtazapine than C allele carriers. When these medications are required, metabolic outcomes are more favourable for this genotype.

CG Intermediate Adrenergic Tone Intermediate

One copy of the C allele; moderately elevated risk of drug-induced weight gain

The mechanism centres on receptor expression: different ADRA2A promoter haplotypes produce up to 5-fold differences in alpha-2A adrenoceptor surface density (Small et al. 2006, PNAS). Higher receptor density strengthens adrenergic inhibition of insulin secretion in pancreatic beta cells and of lipolysis in adipocytes — both effects that can promote fat retention under sympathetically-active metabolic conditions.

Rosmond et al. 2002 (n=284 Swedish men) found heterozygous C/G carriers had significantly higher salivary cortisol after low-dose dexamethasone (p=0.009) and elevated fasting glucose (p=0.017) versus GG homozygotes, suggesting the altered receptor density destabilises HPA axis feedback.

CC Elevated Adrenergic Gain Risk High Risk

Two copies of the C allele; elevated susceptibility to antipsychotic- and antidepressant-induced weight gain

The ADRA2A receptor is expressed on both pancreatic beta cells and adipocytes. When activated by adrenaline or noradrenaline, it inhibits cAMP production, which in beta cells suppresses glucose-stimulated insulin secretion (via the cAMP/TRPM2 axis, Ito et al. 2017) and in fat cells reduces lipolytic flux. Higher receptor expression — as noncoding ADRA2A haplotypes can produce — means a stronger adrenergic brake, and in the context of adrenergically-active medications this translates to greater weight retention.

The mirtazapine finding from Lee et al. 2009 (n=314; p=0.052) points in the same direction: CC genotype patients on mirtazapine gained more weight after 8 weeks of treatment. Mirtazapine itself is a potent histamine H1 and alpha-2 antagonist — the interaction between ADRA2A genotype and mirtazapine's own alpha-2 blockade is likely complex and bidirectional.

An important nuance: the GWAS/metabolic-syndrome literature does not uniformly identify CC as the risk genotype for general obesity — the antipsychotic and antidepressant weight gain signal is the most replicated clinical association. Population-level BMI associations with rs1800544 are not established with consistency.